Odomzo(sonidegib)
Odomzo (sonidegib) is a small molecule pharmaceutical. Sonidegib was first approved as Odomzo on 2015-07-24. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Odomzo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sonidegib phosphate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ODOMZO | sparc | N-205266 RX | 2015-07-24 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
odomzo | New Drug Application | 2020-07-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
skin neoplasms | EFO_0004198 | D012878 | C44 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Basal cell neoplasms | D018295 | 2 | 5 | 1 | — | 3 | 10 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Medulloblastoma | D008527 | 4 | 3 | — | — | — | 6 | ||
Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 3 | — | — | 1 | 4 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 2 | — | — | 1 | 3 |
Essential thrombocythemia | D013920 | D47.3 | 2 | 1 | — | — | — | 2 | |
Polycythemia vera | D011087 | D45 | 2 | 1 | — | — | — | 2 | |
Primary myelofibrosis | D055728 | D47.4 | 2 | 1 | — | — | — | 2 | |
Multiple myeloma | D009101 | C90.0 | — | 2 | — | — | — | 2 | |
Neuroblastoma | D009447 | EFO_0000621 | 2 | 1 | — | — | — | 2 | |
Glioma | D005910 | EFO_0000520 | 2 | 1 | — | — | — | 2 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | C80 | 6 | — | — | — | 1 | 7 | |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | — | — | — | — | 4 |
Prostatic neoplasms | D011471 | C61 | 2 | — | — | — | — | 2 | |
Glioblastoma | D005909 | EFO_0000515 | 2 | — | — | — | — | 2 | |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | — | — | — | 2 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
Lung neoplasms | D008175 | C34.90 | 2 | — | — | — | — | 2 | |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 |
Show 24 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SONIDEGIB |
INN | sonidegib |
Description | Sonidegib is a member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. It has a role as an antineoplastic agent, a SMO receptor antagonist and a Hedgehog signaling pathway inhibitor. It is a member of morpholines, an aminopyridine, a member of biphenyls, a member of benzamides, an aromatic ether, an organofluorine compound and a tertiary amino compound. |
Classification | Small molecule |
Drug class | hedgehog signaling inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1c(C(=O)Nc2ccc(N3C[C@H](C)O[C@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1 |
Identifiers
PDB | — |
CAS-ID | 956697-53-3 |
RxCUI | 1659191 |
ChEMBL ID | CHEMBL2105737 |
ChEBI ID | — |
PubChem CID | 24775005 |
DrugBank | DB09143 |
UNII ID | 0RLU3VTK5M (ChemIDplus, GSRS) |
Target
Agency Approved
SMO
SMO
Organism
Homo sapiens
Gene name
SMO
Gene synonyms
SMOH
NCBI Gene ID
Protein name
smoothened homolog
Protein synonyms
frizzled family member 11, Protein Gx, seven transmembrane helix receptor, smoothened, frizzled family receptor, smoothened, seven transmembrane spanning receptor
Uniprot ID
Mouse ortholog
Smo (319757)
smoothened homolog (P56726)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,236 documents
View more details
Safety
Black-box Warning
Black-box warning for: Odomzo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42,631 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more